Clinical trials: Patients With Major Depressive Disorder
Myasthenia Gravis, Depression
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
This study aimed to examine whether baseline depressive tendency independently predicts post-counseling clinical outcomes in patients with thymoma-associated MG.
- Conditions
- Myasthenia Gravis, Depression, Thymoma, Depression and Quality of Life
- Trial name
- NCT07649187
- Testing
- Psychological counseling intervention
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- Ming-Hsing Chang
Major Depressive Disorder (MDD)
A Study in Patients With Major Depressive Disorder
This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
- Trial name
- NCT03642964
- Testing
- CTC-501
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Chase Therapeutics Corporation
Major Depressive Disorder
Effect of Curcumin as Nutraceutical in Patients of Depression
The purpose of this study is to find the effect of commonly used nutraceutical curcumin ( extract of Curcuma longa, commonly called 'Haldi' in Hindi) in patients of depression.
- Trial name
- NCT01022632
- Testing
- Curcumin, Fluoxetine, Curcumin and Fluoxetine
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Government Medical College, Bhavnagar
Depression - Major Depressive Disorder
Tidal Model-Based ACT for Depression
The purpose of this randomized controlled clinical trial is to evaluate the effectiveness of an Acceptance and Commitment Therapy (ACT)-oriented psychoeducation program based on the Tidal Model in patients diagnosed with…
- Trial name
- TIDAL-ACT (NCT07442253)
- Testing
- Tidal Model-based ACT
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Baskent University
Depression
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
- Trial name
- NCT07485595
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
MDD, Anxiety Disorders
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.
- Trial name
- RECONNECT (NCT04220996)
- Testing
- Vortioxetine
- Where
- 21 sites in Estonia, France and 4 more
- Volunteers
- 100 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Piloting a Novel, Mobile Cognitive Training Tool for Patients With Major Depressive Disorder (MDD)
To assess the efficacy of a mobile-device-deployed cognitive emotional treatment for depression (Moodify) versus an active control treatment (commercially available computer games).
- Trial name
- MDD (NCT02922556)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Major Depressive Disorder
The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression
This prospective observational study (ADeSS-Study3) investigates candidate biomarkers prospectively predicting response to antidepressant medications and prognosis in major depressive disorder (MDD).
- Trial name
- ADeSS_S3 (NCT04342299)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- King's College London
Depression, Depression Moderate
Outcomes Associated With Suicidality in Inpatients With Symptoms of Depression (OASIS-D)
This 6-month, naturalistic cohort study examines male and female inpatients aged 18 to 75 years i) with any form of unipolar depressive episode (cohort 1); ii) clinical diagnosis of a moderate or severe unipolar depressive…
- Conditions
- Depression, Depression Moderate, Depression Severe, Suicidal and Self-injurious Behavior
- Trial name
- OASIS-D (NCT04404309)
- Where
- Germany
- Volunteers
- 3,331 people
- Sponsor
- Charite University, Berlin, Germany
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy…
- Trial name
- NCT02951988
- Testing
- Rapastinel
- Where
- 137 sites in United States
- Volunteers
- 1,304 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depressive Disorder, Major, Anxiety Disorders
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and…
- Trial name
- BASIS (NCT04770454)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Depression
Neurorestorative Effects of Electroconvulsive Therapy (ECT) in Patients With Severe Late Life Depression
To study the potential neurorestorative effects of electroconvulsive therapy (ECT) in depressed patients by measuring brain derived neurotrophic factor (BDNF) serum levels and hippocampal volumes in severely depressed patients…
- Trial name
- NCT02667353
- Testing
- ECT, Etomidate, Succinylcholine
- Volunteers
- 110 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Depressive Disorder
Safety and Efficacy Study in Patients With Major Depressive Disorder
The purpose of this study is to test if GSK163090 can reduce the symptoms of depression. The safety and how well the body can handle the drug will also be investigated.
- Trial name
- NCT00896363
- Testing
- GSK163090 1 mg, GSK163090 3 mg
- Where
- 15 sites in Russia
- Volunteers
- 99 people
- Sponsor
- GlaxoSmithKline
Depression
Effectiveness of Theta-burst Stimulation (TBS) in Patients With Major Depression
Repetitive Transcranial Magnetic Stimulation (rTMS) as well as Theta- Burst Stimulation of the frontal cortex are used to modulate the neuronal excitability in patients with depression.
- Trial name
- NCT01240083
- Testing
- Thetaburst Stimulation, High frequency rTMS
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- University of Regensburg
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
- Trial name
- NCT00042029
- Testing
- MK0869, aprepitant
- Volunteers
- 324 people
- Sponsor
- Merck Sharp & Dohme LLC
Depressive Disorder, Major
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of…
- Trial name
- NCT04984512
- Testing
- Mitizodone Phosphate tablets
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Depression - Major Depressive Disorder, Schizophrenia Disorders
Development and Application of Precision Treatment Strategies for Common Mental Disorders
Schizophrenia (SCH), major depressive disorder (MDD), and bipolar disorder (BPD) are prevalent, disabling psychiatric conditions that not only cause significant suffering for affected individuals and their families but also…
- Conditions
- Depression - Major Depressive Disorder, Schizophrenia Disorders, Bipolar Disorder (BD)
- Trial name
- NCT06729541
- Testing
- Multigenetic Pharmacogenomics-Guided Treatment (MPGT)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Major Depressive Disorder
Lexapro®'s Efficacy After Dose Escalation in Remission Study
The purpose of this study is the evaluation of remission rate between escitalopram 20 mg and 30 mg in patients with major depressive disorder.
- Trial name
- LEADERS (NCT01594866)
- Testing
- escitalopram
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Apathy, Behavioral Variant Frontotemporal Dementia (bvFTD)
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
Apathy is defined as a quantitative reduction in voluntary and goal-directed behavior. To address this, the investigators propose an ethological approach to assess apathy objectively and quantitatively by observing patients in…
- Conditions
- Apathy, Behavioral Variant Frontotemporal Dementia (bvFTD), Disinhibition, Depression - Major Depressive Disorder
- Trial name
- ECOCAPTURE (NCT03272230)
- Testing
- ECOCAPTURE, Cognitive and Behavioral experimental tasks, Neuropsychological assessment
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Treatment-resistant Depression (TRD), Major Depression Disorder
Transcranial Photobiomodulation (tPBM) for Somatic Symptoms in Treatment-Resistant Depression
The primary objective of this study is to evaluate the clinical efficacy of moderate-dose transcranial photobiomodulation (t-PBM) at different frequencies (10 Hz and 40 Hz) in patients with treatment-resistant depression (TRD).
- Trial name
- NCT07543328
- Testing
- transcranial photobiomodulation
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan